En
Non vérifié

Enveric Biosciences

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiquePsychiatrieSantéSanté Publique
29/01/2026
Psychiatrie
Santé
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Marché du travail
Industrie
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
1.00
29/12/2026
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Santé Publique
Industrie
Enveric Biosciences Announces Patent Issuance
1.00
09/12/2025
Biotechnologie
Psychiatrie
Santé
Industrie pharmaceutique
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
1.00
04/12/2025
Psychiatrie
Science
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Événements
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
1.00
26/11/2025
Biotechnologie
Santé Publique
Psychiatrie
Santé
Industrie pharmaceutique
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
1.00
14/11/2025
Biotechnologie
Santé Publique
Santé
Psychiatrie
Marché financier
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
1.00
23/10/2025
Biotechnologie
Santé Publique
Psychiatrie
Santé
Finance
Enveric Biosciences Announces Reverse Stock Split
1.00
16/10/2025
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
1.00
15/10/2025
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Lois/Droit
Industrie
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
1.00
14/10/2025
Psychiatrie
Santé
Technique
Biotechnologie
Industrie
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0